Myocardial Bridging Increases the Risk of Adverse Cardiovascular Events in Patients without Coronary Atherosclerosis

Yang,Hao,Chen,Fang,Leu,Liu,Lin,Horng,Shih
DOI: https://doi.org/10.3390/life14070811
2024-06-27
Life
Abstract:Background: Myocardial bridging (MB) is a congenital coronary anomaly and an important cause of chest pain. The long-term effects of MB on cardiovascular events remain elusive. Methods: We used the National Health Insurance Research Database of Taiwan to conduct an analysis. All patients who had undergone coronary angiography were considered for inclusion. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal ischemic stroke, and cardiovascular death. Results: We identified 10,749 patients from 2008 to 2018 and matched them with an equal number of controls by propensity-score matching. The mean follow-up period was 5.78 years. In patients without coronary artery disease, MB increased the risk of the composite endpoint (hazard ratio [HR]: 1.57, 95% confidence interval [CI]: 1.44–1.72, p < 0.001), which was driven by increased risks of nonfatal myocardial infarction and cardiovascular death. In patients with significant coronary artery disease, MB did not increase the risk of major adverse cardiovascular events. MB was identical to insignificant coronary artery disease from the viewpoint of clinical outcomes. Conclusions: The presence of MB significantly increases cardiovascular risks in patients with normal coronary vessels. Atherosclerotic coronary artery disease mitigates the effect of MB on cardiovascular outcomes. MB can be considered an insignificant coronary artery disease equivalent.
biology
What problem does this paper attempt to address?
The problem this paper attempts to address is whether Myocardial Bridging (MB) increases the risk of Major Adverse Cardiovascular Events (MACEs) in patients without coronary atherosclerosis. Specifically, the research background indicates that Myocardial Bridging is a congenital coronary artery anomaly that can cause symptoms such as chest pain, but its long-term effects are not yet clear. Therefore, this study aims to analyze data from the Taiwan National Health Insurance Research Database to compare the clinical trajectories of patients with and without Myocardial Bridging, with a particular focus on the occurrence of Major Adverse Cardiovascular Events. The primary endpoints of the study include non-fatal myocardial infarction, non-fatal ischemic stroke, and cardiovascular death.